View ValuationCannara Biotech 향후 성장Future 기준 점검 4/6Cannara Biotech은 연간 수입과 매출이 각각 47.7%와 14.4% 증가할 것으로 예상되고 EPS는 연간 36%만큼 증가할 것으로 예상됩니다.핵심 정보47.7%이익 성장률35.99%EPS 성장률Personal Products 이익 성장33.3%매출 성장률14.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트15 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • May 08+ 1 more updateCannara Announces Nicholas Sosiak as Interim CFO During TransitionCannara Biotech Inc. announced that Nicholas Sosiak has been appointed Chief Operating Officer, effective April 23, 2026. Nicholas Sosiak, who has served as the Company's Chief Financial Officer since 2020, will transition fully into his new operational role as Chief Operating Officer while Cannara conducts a search for his successor as CFO. The Company has initiated a search for a new Chief Financial Officer, including both internal and external candidates. Mr. Sosiak will continue to act as the Company’s interim CFO throughout the search and will work closely with his successor to ensure a seamless transition of CFO responsibilities.공지 • Apr 07Cannara Biotech Inc. to Report Q2, 2026 Results on Apr 14, 2026Cannara Biotech Inc. announced that they will report Q2, 2026 results at 7:00 AM, US Eastern Standard Time on Apr 14, 2026공지 • Feb 05Cannara Biotech Inc. announced that it has received CAD 6.3 million in funding from Phoenician Capital LLC and another investorCannara Biotech Inc. announced a non-brokered private placement of 3,000,000 common shares of the Company at a price of CAD 2.10 per Common Share for gross proceeds of CAD 6,300,000 on February 4, 2026. The transaction involves participation from new investor Phoenician Capital LLC. The issue price of the Common Shares represents an approximate 16% premium to the Company’s closing price on February 3, 2026, the last trading day prior to the announcement of the Private Placement. The Common Shares issued in connection with the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws and the policies of the TSXV. No finder’s fees or commissions were paid in connection with the Private Placement. The transaction is subject to final acceptance of the TSX Venture Exchange. The Company further announces that Zohar Krivorot has entered into an agreement to sell, on an exempt basis, 333,333 Common Shares of the Company to Phoenician at a price of CAD 2.10 per Common Share. The Company is not a party to the Secondary Share Sale and will not receive any proceeds from the transaction, which was undertaken solely to offset personal tax losses arising due to the recent vesting of certain restricted share units in the Company. The Common Shares sold to Phoenician under the Secondary Share sale are also subject to restrictions on transfer for a period of four months and one day. Prior to completion of the Secondary Share Sale, the individual investor beneficially owns or exercises control or direction over, directly or indirectly, 25,852,540 Common Shares of the Company, representing approximately 26.99% of the issued and outstanding Common Shares. Upon completion of the Secondary Share Sale, individual investor is expected to beneficially own or exercise control or direction over, directly or Cannara Biotech Inc 2 indirectly, 25,519,207 Common Shares of the Company, representing approximately 25.83% of the issued and outstanding Common Shares, after giving effect to the Private Placement.공지 • Jan 14Cannara Biotech Inc. to Report Q1, 2026 Results on Jan 26, 2026Cannara Biotech Inc. announced that they will report Q1, 2026 results at 7:00 AM, US Eastern Standard Time on Jan 26, 2026공지 • Nov 26Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026.공지 • Nov 18Cannara Biotech Inc. Announces the Passing of Jack M. Kay Member of the Board of DirectorCannara Biotech Inc. announced the passing of Jack M. Kay, a long-serving and highly respected member of the Board of Directors. Mr. Kay, who joined the Board in 2019, contributed more than five decades of leadership experience in pharmaceutical and sales executive management to the Corporation. Mr. Kay spent 35 years at Apotex Inc., where he held several senior executive positions, including Chief Executive Officer, Chief Operating Officer, President, and Vice Chairman. He also served in key leadership roles across the pharmaceutical and biotechnology sectors, including Chairman of Helix Biopharma Corp. and Cangene Corp., and Director of Barr Pharmaceuticals Inc. In addition to his industry contributions, Mr. Kay was a dedicated community leader, notably serving as Chairman of the Humber River Regional Hospital (Toronto) and as an executive member of several healthcare and industry organizations.공지 • Nov 17Cannara Biotech Inc. to Report Q4, 2025 Results on Nov 24, 2025Cannara Biotech Inc. announced that they will report Q4, 2025 results at 7:00 AM, US Eastern Standard Time on Nov 24, 2025공지 • Jul 21Cannara Biotech Inc. to Report Q3, 2025 Results on Jul 28, 2025Cannara Biotech Inc. announced that they will report Q3, 2025 results at 7:00 AM, US Eastern Standard Time on Jul 28, 2025공지 • Apr 16Cannara Biotech Inc. to Report Q2, 2025 Results on Apr 28, 2025Cannara Biotech Inc. announced that they will report Q2, 2025 results at 7:00 AM, US Eastern Standard Time on Apr 28, 2025공지 • Mar 24Cannara Biotech Inc. Announces Appointment of Justin Cohen to Board of DirectorsCannara Biotech Inc. announced the appointment of Mr. Justin Cohen to its board of directors as an independent director. Mr. Cohen will also serve as a member of the Audit Committee. Mr. Cohen is a seasoned executive with a track record of driving transformational growth and providing valuable leadership in brand development, sales and marketing. As Chief Marketing and Chief Commercial Officer at Psycho Bunny, he spearheaded the brand’s evolution from a niche player to a global powerhouse. Under his leadership, revenues increased tenfold over three years, driven by strategic retail expansion, digital acceleration, and brand reinvention. Prior to Psycho Bunny, Mr. Cohen led direct-to-consumer and e-commerce strategy at Keurig Dr Pepper, expanding its digital footprint and scaling revenue across online and omnichannel platforms. He has also held leadership roles at Google, ALDO Group, and Sony Music, where he guided brands through digital transformation and new growth opportunities. Currently, as a senior executive at Cosmetic Physician Partners, Mr. Cohen oversees integrated marketing across a portfolio of over 55 clinics in the United States, ensuring scalable and sustainable expansion. In addition to his corporate leadership, he serves on the board of Dose Juice, advising on commercial strategy, market expansion, and operational efficiency. Mr. Cohen holds degrees in Marketing & Advertising, an MBA, and a master’s in behavioral science from the London School of Economics.공지 • Nov 26Cannara Biotech Inc. Plans to Launch over 20 New Products in High Volume CategoriesCannara Biotech Inc. announced for fiscal 2025, the company plans to launch over 20 new products in high volume categories, including innovative formats like all-in-one vape devices under Tribal and Nugz, and premium infused pre-rolls under Tribal. A rigorous pheno-hunting program underpins these developments, unlocking unique genetics tailored to brand fit, potency, structure, and market appeal. In April 2024, Cannara introduced three new genetics: Neon Sunshine and Bubble Up (Tribal) and Guava Jam (Nugz).공지 • Nov 12Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025.공지 • Nov 13Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024.공지 • Dec 03Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023.이익 및 매출 성장 예측OTCPK:LOVF.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수8/31/2028167N/A343918/31/202713920172648/31/202612313132542/28/2026113101628N/A11/30/2025112121222N/A8/31/2025107131420N/A5/31/2025102161520N/A2/28/20259413511N/A11/30/20248771016N/A8/31/2024826311N/A5/31/2024775210N/A2/29/202473619N/A11/30/2023679-27N/A8/31/2023577-46N/A5/31/2023515-130N/A2/28/2023453-18-5N/A11/30/2022403-22-7N/A8/31/2022362-22-6N/A5/31/2022301-41-2N/A2/28/2022271-362N/A11/30/2021221-322N/A8/31/202117-2-33-2N/A5/31/202111-7-9-6N/A2/28/20215-11-13-10N/A11/30/20203-13-14-9N/A8/31/20203-12-19-9N/A5/31/20203-12-22-8N/A2/29/20202-12-30-9N/A11/30/20192-13N/A-9N/A8/31/20192-12N/A-7N/A8/31/20181-4N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: LOVF.F 의 연간 예상 수익 증가율(47.7%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: LOVF.F 의 연간 수익(47.7%)이 US 시장(16.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: LOVF.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: LOVF.F 의 수익(연간 14.4%)이 US 시장(연간 11.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: LOVF.F 의 수익(연간 14.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: LOVF.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHousehold 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 03:08종가2026/05/11 00:00수익2026/02/28연간 수익2025/08/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cannara Biotech Inc.는 4명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nicholas CortellucciAtrium ResearchNeal GilmerHaywood Securities Inc.Greg McLeishResearch Capital Corporation1명의 분석가 더 보기
공지 • May 08+ 1 more updateCannara Announces Nicholas Sosiak as Interim CFO During TransitionCannara Biotech Inc. announced that Nicholas Sosiak has been appointed Chief Operating Officer, effective April 23, 2026. Nicholas Sosiak, who has served as the Company's Chief Financial Officer since 2020, will transition fully into his new operational role as Chief Operating Officer while Cannara conducts a search for his successor as CFO. The Company has initiated a search for a new Chief Financial Officer, including both internal and external candidates. Mr. Sosiak will continue to act as the Company’s interim CFO throughout the search and will work closely with his successor to ensure a seamless transition of CFO responsibilities.
공지 • Apr 07Cannara Biotech Inc. to Report Q2, 2026 Results on Apr 14, 2026Cannara Biotech Inc. announced that they will report Q2, 2026 results at 7:00 AM, US Eastern Standard Time on Apr 14, 2026
공지 • Feb 05Cannara Biotech Inc. announced that it has received CAD 6.3 million in funding from Phoenician Capital LLC and another investorCannara Biotech Inc. announced a non-brokered private placement of 3,000,000 common shares of the Company at a price of CAD 2.10 per Common Share for gross proceeds of CAD 6,300,000 on February 4, 2026. The transaction involves participation from new investor Phoenician Capital LLC. The issue price of the Common Shares represents an approximate 16% premium to the Company’s closing price on February 3, 2026, the last trading day prior to the announcement of the Private Placement. The Common Shares issued in connection with the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws and the policies of the TSXV. No finder’s fees or commissions were paid in connection with the Private Placement. The transaction is subject to final acceptance of the TSX Venture Exchange. The Company further announces that Zohar Krivorot has entered into an agreement to sell, on an exempt basis, 333,333 Common Shares of the Company to Phoenician at a price of CAD 2.10 per Common Share. The Company is not a party to the Secondary Share Sale and will not receive any proceeds from the transaction, which was undertaken solely to offset personal tax losses arising due to the recent vesting of certain restricted share units in the Company. The Common Shares sold to Phoenician under the Secondary Share sale are also subject to restrictions on transfer for a period of four months and one day. Prior to completion of the Secondary Share Sale, the individual investor beneficially owns or exercises control or direction over, directly or indirectly, 25,852,540 Common Shares of the Company, representing approximately 26.99% of the issued and outstanding Common Shares. Upon completion of the Secondary Share Sale, individual investor is expected to beneficially own or exercise control or direction over, directly or Cannara Biotech Inc 2 indirectly, 25,519,207 Common Shares of the Company, representing approximately 25.83% of the issued and outstanding Common Shares, after giving effect to the Private Placement.
공지 • Jan 14Cannara Biotech Inc. to Report Q1, 2026 Results on Jan 26, 2026Cannara Biotech Inc. announced that they will report Q1, 2026 results at 7:00 AM, US Eastern Standard Time on Jan 26, 2026
공지 • Nov 26Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026Cannara Biotech Inc., Annual General Meeting, Jan 29, 2026.
공지 • Nov 18Cannara Biotech Inc. Announces the Passing of Jack M. Kay Member of the Board of DirectorCannara Biotech Inc. announced the passing of Jack M. Kay, a long-serving and highly respected member of the Board of Directors. Mr. Kay, who joined the Board in 2019, contributed more than five decades of leadership experience in pharmaceutical and sales executive management to the Corporation. Mr. Kay spent 35 years at Apotex Inc., where he held several senior executive positions, including Chief Executive Officer, Chief Operating Officer, President, and Vice Chairman. He also served in key leadership roles across the pharmaceutical and biotechnology sectors, including Chairman of Helix Biopharma Corp. and Cangene Corp., and Director of Barr Pharmaceuticals Inc. In addition to his industry contributions, Mr. Kay was a dedicated community leader, notably serving as Chairman of the Humber River Regional Hospital (Toronto) and as an executive member of several healthcare and industry organizations.
공지 • Nov 17Cannara Biotech Inc. to Report Q4, 2025 Results on Nov 24, 2025Cannara Biotech Inc. announced that they will report Q4, 2025 results at 7:00 AM, US Eastern Standard Time on Nov 24, 2025
공지 • Jul 21Cannara Biotech Inc. to Report Q3, 2025 Results on Jul 28, 2025Cannara Biotech Inc. announced that they will report Q3, 2025 results at 7:00 AM, US Eastern Standard Time on Jul 28, 2025
공지 • Apr 16Cannara Biotech Inc. to Report Q2, 2025 Results on Apr 28, 2025Cannara Biotech Inc. announced that they will report Q2, 2025 results at 7:00 AM, US Eastern Standard Time on Apr 28, 2025
공지 • Mar 24Cannara Biotech Inc. Announces Appointment of Justin Cohen to Board of DirectorsCannara Biotech Inc. announced the appointment of Mr. Justin Cohen to its board of directors as an independent director. Mr. Cohen will also serve as a member of the Audit Committee. Mr. Cohen is a seasoned executive with a track record of driving transformational growth and providing valuable leadership in brand development, sales and marketing. As Chief Marketing and Chief Commercial Officer at Psycho Bunny, he spearheaded the brand’s evolution from a niche player to a global powerhouse. Under his leadership, revenues increased tenfold over three years, driven by strategic retail expansion, digital acceleration, and brand reinvention. Prior to Psycho Bunny, Mr. Cohen led direct-to-consumer and e-commerce strategy at Keurig Dr Pepper, expanding its digital footprint and scaling revenue across online and omnichannel platforms. He has also held leadership roles at Google, ALDO Group, and Sony Music, where he guided brands through digital transformation and new growth opportunities. Currently, as a senior executive at Cosmetic Physician Partners, Mr. Cohen oversees integrated marketing across a portfolio of over 55 clinics in the United States, ensuring scalable and sustainable expansion. In addition to his corporate leadership, he serves on the board of Dose Juice, advising on commercial strategy, market expansion, and operational efficiency. Mr. Cohen holds degrees in Marketing & Advertising, an MBA, and a master’s in behavioral science from the London School of Economics.
공지 • Nov 26Cannara Biotech Inc. Plans to Launch over 20 New Products in High Volume CategoriesCannara Biotech Inc. announced for fiscal 2025, the company plans to launch over 20 new products in high volume categories, including innovative formats like all-in-one vape devices under Tribal and Nugz, and premium infused pre-rolls under Tribal. A rigorous pheno-hunting program underpins these developments, unlocking unique genetics tailored to brand fit, potency, structure, and market appeal. In April 2024, Cannara introduced three new genetics: Neon Sunshine and Bubble Up (Tribal) and Guava Jam (Nugz).
공지 • Nov 12Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025.
공지 • Nov 13Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024.
공지 • Dec 03Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023.